Filtered By:
Therapy: Corticosteroid Therapy
Countries: Canada Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 446 results found since Jan 2013.

2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD
Chest. 2023 Sep 6:S0012-3692(23)05275-3. doi: 10.1016/j.chest.2023.08.014. Online ahead of print.ABSTRACTChronic obstructive pulmonary disease patient care must include confirming a diagnosis with postbronchodilator spirometry. Because of the clinical heterogeneity and the reality that airflow obstruction assessed by spirometry only partially reflects disease severity, a thorough clinical evaluation of the patient should include assessment of symptom burden and risk of exacerbations that permits the implementation of evidence-informed pharmacologic and nonpharmacologic interventions. This guideline provides recommendations...
Source: Chest - September 10, 2023 Category: Respiratory Medicine Authors: Jean Bourbeau Mohit Bhutani Paul Hernandez Shawn D Aaron Marie-France Beauchesne Sophie B Kermelly Anthony D'Urzo Avtar Lal Fran çois Maltais Jeffrey D Marciniuk Sunita Mulpuru Erika Penz Don D Sin Anne Van Dam Joshua Wald Brandie L Walker Darcy D Marcin Source Type: research

Managing Anaphylaxis - Epinephrine, Antihistamines, and Corticosteroids: Over 10 years of C-CARE Registry Data
CONCLUSION: Our findings in this predominantly pediatric population support the early use of epinephrine and suggest a beneficial effect of antihistamines. Corticosteroids use in anaphylaxis should be revisited.PMID:37689113 | DOI:10.1016/j.anai.2023.08.606
Source: Annals of Allergy, Asthma and Immunology - September 9, 2023 Category: Allergy & Immunology Authors: Luca Delli Colli Adnan Al Ali Sofianne Gabrielli Marina Delli Colli Pasquale Mule Benjamin Lawson Ann E Clarke Judy Morris Jocelyn Gravel Rod Lim Edmond S Chan Ran D Goldman Andrew O'Keefe Jennifer Gerdts Derek K Chu Julia Upton Elana Hochstadter Adam Bre Source Type: research

Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study
We described differences in medications, imaging and outcomes.RESULTS: Patients clustered into 7 subgroups. The low comorbidity subgroup (n = 3052, 27.5%) had no comorbidities. The DM-HF-Pulm subgroup had prevalent diabetes, heart failure and chronic lung disease (n = 1710, 15.4%). One disease category defined each remaining subgroup, as follows: pulmonary (n = 1621, 14.6%), diabetes (n = 1281, 11.6%), heart failure (n = 1370, 12.4%), dementia (n = 1038, 9.4%) and cancer (n = 1013, 9.1%). Corticosteroid use ranged from 11.5% to 64.9% in the dementia and pulmonary subgroups, respectively. Piperacillin-tazobactam use ranged ...
Source: cmaj - September 5, 2023 Category: General Medicine Authors: Sarah L Malecki Hae Young Jung Anne Loffler Mark A Green Samir Gupta Derek MacFadden Nick Daneman Ross Upshur Michael Fralick Lauren Lapointe-Shaw Terence Tang Adina Weinerman Janice L Kwan Jessica J Liu Fahad Razak Amol A Verma Source Type: research

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
CONCLUSION AND RELEVANCE: The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD.PMID:37610789 | DOI:10.1001/jamadermatol.2023.2626
Source: Herpes - August 23, 2023 Category: Infectious Diseases Authors: Joseph F Merola Daniel C Butler Thomas Mark Shannon Schneider Yestle Kim Katrina Abuabara Source Type: research

Effect of monitoring adherence to regular inhaled corticosteroid (ICS) alone or in combination with a long-acting {beta}2-agonist (LABA) using electronic methods on asthma outcomes: a narrative systematic review
Conclusion Electronic methods improved adherence to inhaled medications in asthma. EMDs appear to be the most effective technology, followed by mHealth. The adherence improvement was associated with a small clinical improvement. There was inconsistent overlapping of terminology describing electronic methods that require standardisation. Data on the cost-effectiveness of electronic devices and their utilisation in severe asthma are lacking and require further research. PROSPERO registration number CRD42022303069.
Source: BMJ Open - August 16, 2023 Category: General Medicine Authors: Almutairi, M., Marriott, J. F., Mansur, A. Tags: Open access, Respiratory medicine Source Type: research